Novartis’ Exforge Has Late December User Fee Date
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis’ combination anti-hypertensive is already pending in the EU.
You may also be interested in...
Daiichi Sankyo Submits Benicar/Amlodipine Fixed-Dose Combination To FDA
Combination of olmesartan and amlodipine can be used alone or in conjunction with other antihypertensives, firm says.
Daiichi Sankyo Submits Benicar/Amlodipine Fixed-Dose Combination To FDA
Combination of olmesartan and amlodipine can be used alone or in conjunction with other antihypertensives, firm says.
Daiichi Sankyo Submits Benicar/Amlodipine Fixed-Dose Combination To FDA
Daiichi Sankyo submitted an NDA Nov. 27 for a fixed-dose combination of its angiotensin receptor blocker Benicar (olmesartan) and the calcium channel blocker amlodipine (currently marketed by Pfizer as Norvasc). The Japanese drug maker told "The Pink Sheet" DAILY it is seeking a standard review for treatment of hypertension